Industry Sponsored Program
| THURSDAY, MARCH 20, 2025 | ||
| 12:10-13:10 12:10-12:20 12:20-12:40 12:40-13:00 13:00-13:10 | Sanofi Industry Sponsored Symposium | HALL A Spotlight on CIDP: Evolving Perspectives on Disease and the Treatment Landscape Complement’s role in the nervous system Prof. David Cornblath, USA Bridging the Gap: addressing unmet needs in CIDP Prof. Hans Peter Hartung, Germany CIDP and emerging targets and treatments Q&A |  |
| 13:10-14:00 13:10-13:20 13:20-13:35 13:35-13:50 13:50-14:00 | Meet the Expert Session sponsored by argenx | MTE 1 HALL Redefining generalized Myasthenia Gravis: transforming outcomes with precision medicine. Chair & Moderator: Prof. Anna Kostera-Pruszczyk, Poland Welcome & Opening, Latest gMG Guidelines Speaker: Prof. Anna Kostera-Pruszczyk, Poland Redefining generalized Myasthenia Gravis – improving treatment outcomes with Vyvgart Speaker: Dr. Antony Behin, France Real World Experience with Vyvgart in Slovenia: initiation and maintenance treatment strategies Speaker: Dr. Mateja Baruca-Grad, Slovenia Discussion Q&A |  |
| FRIDAY, MARCH 21, 2025 | ||
| 11:10-12:10 | Sanofi Industry Sponsored Symposium (MS) | HALL A Transforming Care: New Frontiers in Detecting and Managing Progression in Multiple Sclerosis The Biological Cascade of Progressive MS Prof. Tjalf Ziemssen, Germany Unmasking the Complexities of non-Relapsing Secondary Progressive Multiple Sclerosis Prof. Melinda Magyari, Denmark Q&A Prof. Tjalf Ziemssen and Prof. Melinda Magyari | |
| 12:20-13:10 12:20-12:40 12:40-13:00 13:00-13:10 | Meet the Expert Session sponsored by Britannia | MTE 1 HALL Supporting patients throughout their Parkinson’s disease journey Apomorphine – a device-aided-therapy (DAT) option before Parkinson’s disease is advanced Prof. Marc Verin, France Intrajejunal levodopa–entacapone–carbidopa (LECIGON®) infusion – a well-established therapy Prof. Irena Rektorova, Czech Republic Q&A |  |
